Ani Pharmaceuticals, Inc revenue by segment ANIP

Annual Quarterly

Ani Pharmaceuticals, Inc splits its revenue into 10 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Total Sales Of Rare Disease Pharmaceutical Products at $160.9 million, 55% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	1,041	291	266	237	247	228	211	197	191
Total Sales Of Rare Disease And Brands	—	—	165 share 62.2%	—	—	129 share 56.7%	—	—	—
Total Sales Of Rare Disease Pharmaceutical Products	—	161 share 55.3%	—	—	—	—	—	—	—
Sales Of Generic Pharmaceutical Products	—	104 +10.7% share 35.9%	99 +9.7% share 37.2%	105 share 44.4%	101 +28.2% share 40.8%	94 share 41.4%	90 share 42.7%	—	79 share 41.2%
Total Sales Of Generics And Other	—	—	—	—	—	—	—	103 share 52.3%	—
Sales Of Cortrophin Gel	—	—	—	75 +42.1% share 31.6%	111 +87.6% share 45.1%	102 share 44.7%	82 share 38.6%	53 share 26.8%	59 share 31.2%
Sales Of ILUVIEN And YUTIQ	—	22 share 7.7%	—	19 +19.5% share 8.1%	20 -28.2% share 8.0%	—	22 share 10.6%	16 share 8.2%	28 share 14.5%
Sales Of Established Brands	—	—	12 -10.5% share 4.4%	12 -50.9% share 5.2%	12 -37.9% share 5.0%	—	13 share 6.2%	25 share 12.7%	20 share 10.4%
Sales Of Established Brand Royalties And Other Revenues	—	11 share 3.9%	—	22 share 9.1%	—	—	—	—	—
Unapproved Products	—	6 +1.7% share 2.1%	6 -6.6% share 2.1%	6 +14.5% share 2.7%	6 +8.3% share 2.6%	6 share 2.6%	6 share 2.9%	6 share 2.8%	6 share 3.1%
Sales Of Generic Other Revenues	—	4 -7.8% share 1.4%	2 -59.0% share 0.6%	4 -12.5% share 1.6%	3 -46.7% share 1.1%	4 share 1.9%	4 share 1.9%	4 share 2.2%	5 share 2.7%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ANIP (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Princeton, NJ
SEC filer status: Large accelerated filer
SEC CIK: 1023024
Former names: BIOSANTE PHARMACEUTICALS INC (until Jul 18, 2013); BEN ABRAHAM TECHNOLOGIES INC (until Dec 23, 1999)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.